Company: IMNN
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022120
Chunk: 5

Company: Imunon, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 8
Chunk 5
---
maker (“CODM”) has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions
about allocating resources and assessing performance for the entire Company based on condensed consolidated financial information. Consequently,
the Company views the entire organization as one reportable segment and the strategic purpose of all operating activities (including general and
administrative expenses) is to support that one segment. As a pre-revenue research and development company, the CODM evaluates company-wide
performance and allocates resources based on non-financial research and development milestones achieved, and to a lesser extent, financial
measures of performance such as clinical development (research and development expenses) and general and administrative expenses incurred.
The CODM does not generally evaluate the Company’s performance using asset or historical cash flow information.

    10

The
table below provides a summary of the significant expense categories and consolidated net loss details provided to the CODM (in thousands):

 Schedule
of Significant Expense Categories and Consolidated Net Loss

    2025  
    2024  

    For the nine months ended September 30, 

    (In thousands)  
    Change Increase (Decrease) 

    2025  
    2024  

    Operating Expenses: 

    Clinical Research 

    OVATION 2 and MRD Trials 
    $212  
    $1,139  
    $(927) 
     (81.4)%
  
    OVATION 3 Trial 
     695  
     -  
     695  
     -%
  
    PlaCCine Vaccine Phase 1 Trial 
     42  
     1,412  
     (1,370) 
     (97.0)%
  
    Other Clinical and Regulatory 
     1,387  
     1,900  
     (513) 
     (27.0)%
  
    Subtotal 
     2,336  
     4,451  
     (2,115) 
     (47.5)%
  
    Non-Clinical R&D and CMC 

    OVATION Program 
     2,209  
     851  
     1,358  
     159.6%
  
    PlaCCine Vaccine Program 
     -  
     2,554  
     (2,554) 
     -%